Clinical Trials Logo

Solid Tumor clinical trials

View clinical trials related to Solid Tumor.

Filter by:

NCT ID: NCT06112041 Not yet recruiting - Solid Tumor Clinical Trials

The Prospective Clinical Study of Precision PRaG Therapy in Elderly Patients With Advanced Solid Malignant Tumors (PRaG9.0)

Start date: October 25, 2023
Phase: Phase 2
Study type: Interventional

This is an open-label, single-arm, Phase II investigator-initiated trial of hypofractionated radiotherapy combined with PD-L1 inhibitor sequential GM-CSF and thymopentin for treatment of elderly patients with advanced solid tumors, when the HER-2 positive patients are treated with extra antibody-drug conjugate.

NCT ID: NCT06041035 Not yet recruiting - Solid Tumor Clinical Trials

A Study of QLS31905 Combination Chemotherapy as First-Line Treatment in Patients With Advanced Solid Tumors

Start date: October 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This study aims to evaluate the efficacy and safety of QLS31905 plus chemotherapy in patients with Claudin18.2-positive advanced solid tumors.

NCT ID: NCT06010342 Not yet recruiting - Solid Tumor Clinical Trials

A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients

Start date: May 2024
Phase: Phase 2
Study type: Interventional

The main objective of the study will be to evaluate the efficacy of TL118 in participants with solid tumors harboring NTRK gene fusions

NCT ID: NCT05982522 Not yet recruiting - Solid Tumor Clinical Trials

IN10018 Combination Therapy in Previously-treated Solid Tumors

Start date: August 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase Ib/II, randomized, open-label, multicenter clinical trial to evaluate the antitumor activities, safety, tolerability and pharmacokinetics (PK) of IN10018 in combination with taxane and anti-PD-1/L1 monoclonal antibody in patients with locally advanced or metastatic solid tumors who have failed in or been intolerant to at least one line of standard therapy. This study will be firstly carried out in previously-treated non-small cell lung cancer (NSCLC) population,

NCT ID: NCT05971589 Not yet recruiting - Solid Tumor Clinical Trials

A Clinical Study on LM103 Injection for the Treatment of Advanced Solid Tumors

Start date: August 2023
Phase: Early Phase 1
Study type: Interventional

This study is an open exploratory clinical study to evaluate the safety, tolerance, immune response, and initial efficacy of autologous tumor infiltrating lymphocyte LM103 injection in advanced solid tumor patients. The research treatment includes fludarabine and cyclophosphamide, autologous tumor infiltrating lymphocytes (TILs) infusion, and Interleukin-2 therapy.

NCT ID: NCT05971576 Not yet recruiting - Solid Tumor Clinical Trials

A Clinical Study on TILs for the Treatment of Advanced Solid Tumors

Start date: August 2023
Phase: Early Phase 1
Study type: Interventional

This study is an open exploratory clinical study to evaluate the safety, tolerance, immune response, and initial efficacy of autologous tumor infiltrating lymphocyte LM103 injection in advanced solid tumor patients . The research treatment includes fludarabine and cyclophosphamide, autologous tumor infiltrating lymphocytes (TILs) infusion, and Interleukin-2 therapy.

NCT ID: NCT05954091 Not yet recruiting - Solid Tumor Clinical Trials

OH2 Administered by Intratumoral Injection

Start date: September 1, 2023
Phase: Phase 1
Study type: Interventional

This study will be a Phase 1, multi-center, open-label, dose escalation followed by the recommended phase 2 dose (RP2D) expansion study to characterize safety, tolerability, biodistribution, virus shedding and preliminary efficacy of intratumoral injection of OH2 in patients with locally advanced/metastatic solid tumors.

NCT ID: NCT05940116 Not yet recruiting - Clinical trials for Non-Small Cell Lung Cancer

A Phase I Clinical Study of HS-20117 in Participants With Advanced Solid Tumors

Start date: July 20, 2023
Phase: Phase 1
Study type: Interventional

HS-20117 is a fully-human EGFR-MET immunoglobulin G1(IgG1)-like bispecific antibody. The purpose of study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of HS-20117 as a monotherapy for participants with advanced solid tumors.

NCT ID: NCT05843305 Not yet recruiting - Solid Tumor Clinical Trials

A Study of BPI-452080 in Subjects With Solid Tumors

Start date: April 28, 2023
Phase: Phase 1
Study type: Interventional

This open-label Phase 1 study will evaluate the efficacy and safety of BPI-452080 in patients with Solid Tumors

NCT ID: NCT05831033 Not yet recruiting - Solid Tumor Clinical Trials

Safety and Efficacy of an Autologous Tumor Infiltrating Lymphocyte (TIL) Therapy in Patients With Advanced Solid Tumors

Start date: May 15, 2023
Phase: Early Phase 1
Study type: Interventional

Multicenter, single arm, non-randomized, prospective, open label, interventional study evaluating adoptive cell therapy (ACT) with autologous tumor infiltrating lymphocytes (TIL) infusion (BEN101) followed by IL-2 after a non-myeloablative (NMA) lymphodepletion preparative regimen for the treatment of patients with recurrent and/or metastatic solid tumor.